Bioinformatics analysis of Ras homologue enriched in the striatum, a potential target for Huntington's disease therapy.

Int J Mol Med 2019 Dec 15;44(6):2223-2233. Epub 2019 Oct 15.

Institute of Molecular Biology and Pathology of The National Research Council of Italy, I‑00185 Rome, Italy.

Huntington's disease (HD) is a lethal neurodegenerative disorder for which no cure is available yet. It is caused by abnormal expansion of a CAG triplet in the gene encoding the huntingtin protein (Htt), with consequent expansion of a polyglutamine repeat in mutated Htt (mHtt). This makes mHtt highly unstable and aggregation prone. Soluble mHtt is linked to cytotoxicity and neurotoxicity, whereas mHtt aggregates are thought to be neuroprotective. While Htt and mHtt are ubiquitously expressed throughout the brain and peripheral tissues, HD is characterized by selective degradation of the corpus striatum, without notable alterations in peripheral tissues. Screening for mRNAs preferentially expressed in rodent striatum led to the discovery of a GTP binding protein homologous to Ras family members. Due to these features, the newly discovered protein was termed Ras Homolog Enriched in Striatum (RHES). The aetiological role of RHES in HD has been ascribed to its small ubiquitin‑like modifier (SUMO)‑E3 ligase function. RHES sumoylates mHtt with higher efficiency than wild‑type Htt, thereby protecting mHtt from degradation and increasing the amounts of the soluble form. Although RHES is an attractive target for HD treatment, essential information about protein structure and function are still missing. With the aim of investigating RHES 3D structure and function, bioinformatic analyses and molecular modelling have been performed in the present study, based on which, RHES regions predicted to be involved in the interaction with mHtt or the SUMO‑E2 ligase Ubc9 have been identified. These regions have been used to design peptides aimed at inhibiting RHES interactions and, therefore, mHtt sumoylation; in turn, these peptides will be used to develop small molecule inhibitors by both rational design and virtual screening of large compound libraries. Once identified, RHES sumoylation inhibitors may open the road to the development of therapeutic agents against the severe, and currently untreatable, HD.

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijmm.2019.4373DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6844632PMC
December 2019
Get 20% Off Journals at LWW.com

Similar Publications

Exposure of R6/2 mice in an enriched environment augments P42 therapy efficacy on Huntington's disease progression.

Neuropharmacology 2021 Jan 28;186:108467. Epub 2021 Jan 28.

MMDN, Univ Montpellier, EPHE, INSERM, Montpellier, France. Electronic address:

Huntington's disease (HD) is due to a mutation in the gene encoding for Huntingtin protein generating polyQ domain extension. Mutant Htt (mHtt) leads to important dysfunction of the BDNF/TrkB signaling. We previously described the 23aa Htt fragment P42, that attenuated the pathological phenotypes induced by mHtt. Read More

View Article and Full-Text PDF
January 2021

Influence of process parameters on hydrothermal modification of soybean residue: Insight into the nutrient, solid biofuel, and thermal properties of hydrochars.

J Environ Manage 2021 Apr 27;283:111981. Epub 2021 Jan 27.

Shanghai Key Laboratory of Atmospheric Particle Pollution and Prevention (LAP(3)), Department of Environmental Science and Engineering, Fudan University, Shanghai, 200438, China; Shanghai Technical Service Platform for Pollution Control and Resource Utilization of Organic Wastes, Shanghai, 200438, China; Shanghai Institute of Pollution Control and Ecological Security, Shanghai, 200092, China. Electronic address:

Soybean (SB) solid residue after oil extraction was investigated in a hydrothermal modification process to provide an eco-friendly solution to SB solid waste disposal for an actual environmental management effort. SB hydrochars (HCs) were derived either by conventional heating hydrothermal treatment (HTT) under intense conditions (200, 250, and 300 °C for 2 h) or by microwave-assisted hydrothermal treatment (MHTT) under mild conditions (160, 190, and 220 °C for 1 h). Physicochemical properties of SB HCs and the transformation of nitrogen (N) and phosphorus (P) functionalities during HTT and MHTT were characterized using several tools. Read More

View Article and Full-Text PDF

Gossypol, a novel modulator of VCP, induces autophagic degradation of mutant huntingtin by promoting the formation of VCP/p97-LC3-mHTT complex.

Acta Pharmacol Sin 2021 Jan 25. Epub 2021 Jan 25.

Key Laboratory of Metabolism and Molecular Medicine, the Ministry of Education, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.

Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by toxic aggregates of mutant huntingtin protein (mHTT) in the brain. Decreasing mHTT is a potential strategy for therapeutic purpose of HD. Valosin-containing protein (VCP/p97) is a crucial regulator of proteostasis, which regulates the degradation of damaged protein through proteasome and autophagy pathway. Read More

View Article and Full-Text PDF
January 2021

Discovery of the First Druggable GPR52 Antagonist to Treat Huntington's Disease.

J Med Chem 2021 Jan 14;64(2):938-940. Epub 2021 Jan 14.

Medical Affairs, Kyowa Pharmaceutical Industry Co., Ltd., Osaka 530-0005, Japan.

GPR52 is an orphan G protein-coupled receptor (GPCR) highly expressed in the brain, especially in the striatum, and represents an emerging therapeutic target for Huntington's disease (HD), an incurable monogenic neurodegenerative disorder caused by the mutation of the huntingtin (mHTT) gene. This Viewpoint discusses the discovery, published in this journal, that a highly potent and specific GPR52 antagonist was identified through high-throughput screening and structure-activity relationship study, which diminishes not only mHTT protein levels, but also ameliorates HD-like phenotypes in the animal disease models. This strategy offers intriguing promise as a surprising approach for HD therapy, where nucleic acid medicine approaches such as small interference RNAs have been the main focus and encounter obstacles such as delivery efficiency. Read More

View Article and Full-Text PDF
January 2021

Spatiotemporal analysis of soluble aggregates and autophagy markers in the R6/2 mouse model.

Sci Rep 2021 Jan 8;11(1):96. Epub 2021 Jan 8.

Neuroscience Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Jakkur, Bangalore, India.

Maintenance of cellular proteostasis is vital for post-mitotic cells like neurons to sustain normal physiological function and homeostasis, defects in which are established hallmarks of several age-related conditions like AD, PD, HD, and ALS. The Spatio-temporal accumulation of aggregated proteins in the form of inclusion bodies/plaques is one of the major characteristics of many neurodegenerative diseases, including Huntington's disease (HD). Toxic accumulation of HUNTINGTIN (HTT) aggregates in neurons bring about the aberrant phenotypes of HD, including severe motor dysfunction, dementia, and cognitive impairment at the organismal level, in an age-dependent manner. Read More

View Article and Full-Text PDF
January 2021